BR112012018342A2 - "valor de previsão do polimorfismo do gene il28b combinado com a quantificação de ip-10 no soro pré-tratamento para resposta ao peginterferon e à ribavirina aprimorada em relação a qualquer desses biomarcadores isoladamente." - Google Patents

"valor de previsão do polimorfismo do gene il28b combinado com a quantificação de ip-10 no soro pré-tratamento para resposta ao peginterferon e à ribavirina aprimorada em relação a qualquer desses biomarcadores isoladamente."

Info

Publication number
BR112012018342A2
BR112012018342A2 BR112012018342A BR112012018342A BR112012018342A2 BR 112012018342 A2 BR112012018342 A2 BR 112012018342A2 BR 112012018342 A BR112012018342 A BR 112012018342A BR 112012018342 A BR112012018342 A BR 112012018342A BR 112012018342 A2 BR112012018342 A2 BR 112012018342A2
Authority
BR
Brazil
Prior art keywords
response
peginterferon
ribavirin
quantitation
relative
Prior art date
Application number
BR112012018342A
Other languages
English (en)
Inventor
Gregory Charles Fanning
Jeroen Aerssens
Michael W Fried
Original Assignee
Janssen R&D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R&D Ireland filed Critical Janssen R&D Ireland
Publication of BR112012018342A2 publication Critical patent/BR112012018342A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

valor de previsão do polimorfismo do gene il28b combinado com a quantificação de ip-10 no soro pré-tratamento para resposta ao peginterferon e à ribavirina aprimorada em relação a qualquer desses biomarcadores isoladamente. a presente invenção refere-se a um método para combinar a determinação do genótipo de il28b com a medição do nível de ip-10 no soro pré-tratamento para prever o resultado de uma resposta virológica sustentada (svr) ou não resposta ao peginterferon e à ribavirina para pacientes individuais infectados com hcv.
BR112012018342A 2009-12-22 2010-12-21 "valor de previsão do polimorfismo do gene il28b combinado com a quantificação de ip-10 no soro pré-tratamento para resposta ao peginterferon e à ribavirina aprimorada em relação a qualquer desses biomarcadores isoladamente." BR112012018342A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09180387 2009-12-22
EP10175297 2010-09-03
PCT/EP2010/070429 WO2011076814A1 (en) 2009-12-22 2010-12-21 Predictive value of il28b gene polymorphism combined with pretreatment serum ip-10 quantification for response to peginterferon and ribavirin is enhanced in comparison with any of these biomarkers alone

Publications (1)

Publication Number Publication Date
BR112012018342A2 true BR112012018342A2 (pt) 2017-01-10

Family

ID=43566688

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018342A BR112012018342A2 (pt) 2009-12-22 2010-12-21 "valor de previsão do polimorfismo do gene il28b combinado com a quantificação de ip-10 no soro pré-tratamento para resposta ao peginterferon e à ribavirina aprimorada em relação a qualquer desses biomarcadores isoladamente."

Country Status (11)

Country Link
US (1) US20120252695A1 (pt)
EP (1) EP2516673B1 (pt)
JP (2) JP5956347B2 (pt)
CN (1) CN102770557B (pt)
AU (1) AU2010334918B2 (pt)
BR (1) BR112012018342A2 (pt)
CA (1) CA2784781A1 (pt)
ES (1) ES2554359T3 (pt)
RU (1) RU2567806C2 (pt)
WO (1) WO2011076814A1 (pt)
ZA (1) ZA201204623B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271542A1 (en) * 2011-10-05 2014-09-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Service Genetic marker for predicting prognosis in patients infected with hepatitis c virus
WO2013148272A1 (en) 2012-03-28 2013-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A NOVEL INTERFERON-λ4 (IFNL4) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF
CN102816838A (zh) * 2012-07-06 2012-12-12 吉林艾迪康医学检验所有限公司 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒
CN104178582A (zh) * 2014-06-12 2014-12-03 江崇才 一种丙型肝炎病毒的试剂盒及其检测方法
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459647B (zh) * 2009-05-21 2015-05-06 默沙东公司 与干扰素-α应答有关的遗传标记
AU2010277239A1 (en) * 2009-07-31 2012-02-02 Centre Hospitalier Universitaire Vaudois Methods for diagnosing or predicting hepatitis C outcome in HCV infected patients

Also Published As

Publication number Publication date
JP2016136965A (ja) 2016-08-04
JP2013514796A (ja) 2013-05-02
CN102770557B (zh) 2015-08-19
EP2516673B1 (en) 2015-09-23
CN102770557A (zh) 2012-11-07
EP2516673A1 (en) 2012-10-31
ES2554359T3 (es) 2015-12-18
ZA201204623B (en) 2014-11-26
AU2010334918A1 (en) 2012-06-21
US20120252695A1 (en) 2012-10-04
AU2010334918B2 (en) 2015-04-02
CA2784781A1 (en) 2011-06-30
WO2011076814A1 (en) 2011-06-30
JP5956347B2 (ja) 2016-07-27
RU2567806C2 (ru) 2015-11-10
RU2012131339A (ru) 2014-01-27

Similar Documents

Publication Publication Date Title
BR112012018342A2 (pt) "valor de previsão do polimorfismo do gene il28b combinado com a quantificação de ip-10 no soro pré-tratamento para resposta ao peginterferon e à ribavirina aprimorada em relação a qualquer desses biomarcadores isoladamente."
BR112012001931A2 (pt) métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv
BR112012024958A2 (pt) encaminhamento de palavra crítica com previsão adaptativa
BR112013030606A2 (pt) biomarcadores para terapia inibidora de hedgehog
DK2114990T5 (da) Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor
BRPI0918653A2 (pt) combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.
DE112007001398A5 (de) Kalibriergewichtsanordnung für eine elektronische Waage
MX339427B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico.
BR112013024880A2 (pt) seleção de tratamento de hcv
ATE523602T1 (de) Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen
BRPI0519519A2 (pt) procedimento para detectar o aumento de isoformas de apolipoproteÍna "ai" oxidadas e kit para determinar o aumento da isoforma
Lewindon et al. Cystic Fibrosis—Cirrhosis, Portal Hypertension, and Liver Biopsy: ReplyΔ
DE602007011542D1 (de) Schätzsystem für einen Indikator für Körperzusammensetzungen
NZ599373A (en) Biomarkers for predicting rapid response to hcv treatment
BRPI0922159A2 (pt) instrumento com teclado
WO2008039445A3 (en) Polymorphisms in the human xbp-1 gene are associated with inflammatory bowel disease
De Bock et al. In vitro cytochrome p450 activity decreases in children with high pediatric end-stage liver disease scores
GB0713364D0 (en) Abnormal blood conditions
BR112014027413A2 (pt) biomarcadores para terapia com inibidor de iap
DE602006017112D1 (de) Quenchsystem für metallurgische gase
Dietz et al. Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy
Martinot-Peignoux et al. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C
Su et al. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin
WO2007110869A3 (en) Methods and kits for determining predisposition to warfarin resistance
Halfon et al. Quantification of genotype 4 serum samples: impact of hepatitis C virus genetic variability

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]